Understanding, assessing and treating Raynaud's phenomenon

Current Opinion in Rheumatology

Volumn 17, Issue 6, 2005, Pages 752-760

  Boin, Francesco ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 adrenergic receptor; Raynaud's; Scleroderma; Vasospasm

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BOSENTAN; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; ENDOTHELIN RECEPTOR ANTAGONIST; ESTROGEN; FASUDIL; GENISTEIN; GUANETHIDINE; H 1152; ILOPROST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NIFEDIPINE; OPC 28326; PHENOXYBENZAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; PROSTANOIC ACID DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RESERPINE; RHO KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; ANEMOMETRY; BLOOD FLOW; CELL SURFACE; CLINICAL TRIAL; COOLING; DISEASE EXACERBATION; DRUG EFFECT; ENDOTHELIUM LESION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FINGER; HUMAN; ISCHEMIA; LASER DOPPLER FLOWMETRY; LASER DOPPLER SKIN PERFUSION PRESSURE; LOW LEVEL LASER THERAPY; META ANALYSIS; MICROANGIOPATHY; PATHOGENESIS; PERFUSION; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RAYNAUD PHENOMENON; REVIEW; SCINTIGRAPHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SPINAL CORD STIMULATION; SYMPATHECTOMY; SYMPATHETIC BLOCKING; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASOSPASM;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RAYNAUD DISEASE; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 27544509478     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000179944.35400.6e     Document Type: Review

References (77)

1. Wigley FM. Clinical practice: Raynaud's phenomenon. N Engl J Med 2002; 347:1001-1008.
2. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10:485-488.
3. Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003; 29:293-313.
4. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002; 14:686-693.
5. Lewis T. Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 1929; 15:7-101.
6. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatol 2005; 44: 587-596. This is a highly recommended comprehensive and current review of pathogenesis in Raynaud's phenomenon.
7. White CR, Haidekker MA, Stevens HY, Frangos JA. Extracellular signal-regulated kinase activation and endothelin-1 production in human endothelial cells exposed to vibration. J Physiol 2004; 555:565-572. This is the first report describing transduction of vibrational energy into a biochemical signal inside endothelial cells. Fluid vibratory forces applied to the endothelium induce extracellular signal-regulated kinase (ERK 1/2) phosphorylation and endothelin-1 release.
8. Ojha M. Wall shear stress temporal gradient and anastomotic intimal hyperplasia. Circ Res 1994; 74:1227-1231.
9. Loth F, Fischer PF, Arslan N, et al. Transitional flow at the venous anastomosis of an arteriovenous graft: potential activation of the ERK1/2 mechanotransduction pathway. Biomech Eng 2003; 125:49-61.
10. Kahaleh B. Progress in research into systemic sclerosis. Lancet 2004; 364:561-562.
11. Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004; 50:1578-1585. This article suggests that PTK activity and intracellular VSM phosphorylation are implicated in the increased contractile response to cold and adrenergic agonists in patients with primary Raynaud's phenomenon.
12. Furspan PB, Chatterjee S, Mayes MD, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatol 2005; 44:488-494.
13. Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43:1886-1890.
14. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003; 29:275-291.
15. Chotani MA, Flavahan S, Mitra S, et al. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000; 278:H1075-H1083.
16. ++ of contractile proteins. These effects and cold-induced vasospasm are clearly reversed by Rho-kinase inhibitors supporting the potential use of these molecules to treat Raynaud's phenomenon.
17. Teixeira CE, Webb RC. Cold-induced vasoconstriction: a Waltz pairing Rho-kinase signaling and alpha2-adrenergic receptor translocation. Circ Res 2004; 94:1273-1275.
18. Bailey SR, Mitra S, Flavahan S, et al. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005 [Epub ahead of print]. This extremely important study confirms that the initial trigger for Rho/Rho kinase signaling is provided by a rapid increase of ROS in smooth muscle cells after cold exposure. ROS inhibitors were able to abolish cold-induced increase in α2c-adrenoreceptor constrictor activity. These results prompt reconsideration of anti-oxidant treatment strategies in Raynaud's phenomenon.
19. Denton CP, Bunce TD, Darado MB. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatol 1999; 38:309-315.
20. Mavrikakis ME, Lekakis JP, Papamichael CM. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res 2003; 73:3-7.
21. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91:391-392.
22. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005; 127:1446-1452.
23. Chotani MA, Mitra S, Eid AH, et al. Distinct cAMP signaling pathways differentially regulate alpha2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells. Am J Physiol Heart Circ Physiol 2005; 288:H69-H76. Findings in this study suggest that exposure to serum induces expression of α2c-adrenergic receptors on VSMs. Similarly enhanced vasoconstrictive responses to cooling can result in vivo from traumatic or inflammatory events exposing VSMs to serum.
24. Stephens DP, Aoki K, Kosiba WA, Johnson JM. Nonnoradrenergic mechanism of reflex cutaneous vasoconstriction in men. Am J Physiol Heart Circ Physiol 2001; 280:H1496-H1504.
25. Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129:208-211.
26. Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005; 31:177-186. Comprehensive review of the extrinsic regulation of vascular tone by neuropeptides and estrogen. This article also discusses the controversial role of estrogen in regulation of vascular tone.
27. Momoi H, Ikomi F, Ohhashi T. Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. Jpn J Physiol 2003; 53:193-203.
28. Huang A, Sun D, Wu Z, et al. Estrogen elicits cytochrome P450-mediated flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt phosphorylation in genomic regulation. Circ Res 2004; 94:245-252.
29. Lekakis J, Papamichael C, Mavrikakis M, et al. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82:1555-1557.
30. Lekakis J, Mavrikakis M, Papamichael C, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998; 136:905-912.
31. Bunker CB, Goldsmith PC, Leslie TA, et al. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996; 134:399-406.
32. Stephens DP, Saad AR, Bennett LA, et al. Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. Am J Physiol Heart Circ Physiol 2004; 287:H1404-H1409. This study highlights the role of non-noradrenergic molecules in mediating cold-induced vasoconstriction.
33. Wigley FM, Flavahan NA. Raynaud's phenomenon. Rheum Dis Clin North Am 1996; 22:765-781.
34. Mukerjee D, Yap LB, Ong V, et al. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004; 63:1627-1631. This article revisits the issue of cooling-induced systemic arterial vasospasm. Previous studies showing that pulmonary arterial vasospasm does not occur following cold exposure are confirmed.
35. Wise RA, Wigley F, Newball HH, Stevens MB. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon. Chest 1982; 81:695-698.
36. Shuck JW, Oetgen WJ, Tesar JT. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis. Am J Med 1985; 78:221-227.
37. Pope JE, Fenlon D, Furst D, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; 2: CD000956.
38. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2-C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50:3994-4001. Laboratory-based investigation providing evidence that α2c-adrenoreceptor blockade can improve recovery from cold-triggered Raynaud's phenomenon events.
39. Wigley F, Czerwiec F. Multi-center, blinded, randomized, placebo-controlled study of OPC-28326, a selective alpha-adrenergic antagonist, in patients with Raynaud's phenomenon. Arthritis Rheum 2004; 9:3692-1854.
40. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Exp Rev Cardiovasc Ther 2005; 3:441-451.
41. Inokuchi K, Ito A, Fukumoto Y, et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004; 44:275-277.
42. Tanaka K, Minami H, Kota M, et al. Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride. Neurosurgery 2005; 56:214-223.
43. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatol 2005; 44:145-150. This is a meta-analysis confirming the relatively modest effect of CCBs in treating Raynaud's phenomenon.
44. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44:1841-1847.
45. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41:670-677.
46. Garcia Hernandez FJ, Ocana Medina C, Mateos Romero L, et al. Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases. Med Clin (Barc) 2004; 122:501-504.
47. Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatol 2004; 43:229-233. Valuable contribution broadening the experience on the successful use of prostanoids in treating severe digital ischemia and Raynaud's phenomenon in children.
48. 2 in treating severe Raynaud's phenomenon.
49. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001; 19:503-508.
50. Simms RW, Farber H, Kissin E, et al. Intravenous epoprostenol for severe digital ischemia in scleroderma. Arthritis Rheum 2004; 9:1702.
51. Beltran E, Perez Garcia C, Blanch J, et al. Alprostadil IV treatment of severe Raynaud's phenomenon in collagen diseases. Arthritis Rheum 2004; 9:1704.
52. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005 [Epub ahead of print]
53. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41:851-876.
54. McLaughlin W, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244-249.
55. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
56. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985-3993. This study provides evidence that endothelin-1 inhibitors can prevent ischemic ulcers in scleroderma. No clinical benefit was shown in terms of number and severity of Raynaud's phenomenon attacks, however.
57. Ramos-Casals M, Brito-Zeron P, Nardi N, et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatol 2004; 43:1454-1456.
58. Mehats C, Andersen CB, Filopanti M, et al. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002; 13:29-35.
59. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 2005; 171:1292-1297.
60. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 2003; 48:282-283.
61. Kumana CR, Cheung GT, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004; 63:1522-1524.
62. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005; 69:178-179.
63. Rajagopalan S, Pfenninger D, Somers E, et al. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol 2003; 92:1310-1315.
64. Rey J, Cretel E, Jean R, et al. Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia. Rheumatol 2003; 42:601-602.
65. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatol 2001; 40:1038-1043.
66. Garcia-Porrua C, Margarinos CC, Gonzalez-Gay MA. Raynaud's phenomenon and serotonin reuptake inhibitors. J Rheumatol 2004; 31:2090.
67. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest 2004; 34:312-313. Topical botulinum toxin injections in treating Raynaud's phenomenon are described in this report. Although this novel application is very interesting, more investigations are required before recommending it as routine clinical practice.
68. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281:H2124-H2132.
69. Sibell DM, Colantonio AJ, Stacey BR. Successful use of spinal cord stimulation in the treatment of severe Raynaud's disease of the hands. Anesthesiology 2005; 102:225-227.
70. Hirschl M, Katzenschlager R, Francesconi C, Kundi M. Low level laser therapy in primary Raynaud's phenomenon: results of a placebo controlled, double blind intervention study. J Rheumatol 2004; 31:2408-2412.
71. al-Awami M, Schillinger M, Maca T, et al. Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon. Vasa 2004; 33:25-29.
72. Murray AK, Herrick AL, King TA. Laser Doppler imaging: a developing technique for application in the rheumatic diseases. Rheumatol 2004; 43:1210-1218. The new technology of laser Doppler imaging appears to provide a more reproducible method for assessing and characterizing digital blood flow in Raynaud's phenomenon.
73. Anderson ME, Moore TL, Lunt M, Herrick AL. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging: a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatol 2004; 43:986-991.
74. Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatol 2002; 41:324-328.
75. Ziegler S, Gschwandtner M, Zoch C, et al. Laser Doppler anemometry distinguishes primary Raynaud phenomenon from VWF syndrome. Microvasc Res 2004; 68:203-208.
76. Kanetaka T, Komiyama T, Onozuka A, et al. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon. Eur J Vasc Endovasc Surg 2004; 27:414-416.
77. Sarikaya A, Ege T, Firat MF, et al. Assessment of digital ischaemia and evaluation of response to therapy by 99mTc sestamibi limb scintigraphy after local cooling of the hands in patients with vasospastic Raynaud's syndrome. Nucl Med Commun 2004; 25:207-211.